Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. On that note, here are three stocks getting more buzz than they deserve and some you should buy instead.

Ryder (R)

One-Month Return: +16.2%

As one of the first companies to introduce the idea of leasing trucks, Ryder (NYSE: R) provides rental vehicles to businesses and delivers packages directly to homes or businesses.

Why Are We Wary of R?

1. The company has faced growth challenges as its 3% annual revenue increases over the last two years fell short of other industrials companies
2. Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 19.7%
3. Cash-burning tendencies make us wonder if it can sustainably generate shareholder value

Ryder’s stock price of $270.24 implies a valuation ratio of 18.3x forward P/E. To fully understand why you should be careful with R, check out our full research report (it’s free).

Timken (TKR)

One-Month Return: +12.5%

Established after the founder noticed the difficulty freight wagons had making sharp turns, Timken (NYSE: TKR) is a provider of industrial parts used across various sectors.

Why Do We Think TKR Will Underperform?

1. Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
2. Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
3. Eroding returns on capital suggest its historical profit centers are aging

At $132.05 per share, Timken trades at 21.7x forward P/E. Check out our free in-depth research report to learn more about why TKR doesn’t pass our bar.

Azenta (AZTA)

One-Month Return: +24.8%

Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ: AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials.

Why Should You Dump AZTA?

1. Sales tumbled by 1.6% annually over the last two years, showing market trends are working against it during this cycle
2. Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
3. Negative free cash flow raises questions about the return timeline for its investments

Azenta is trading at $22.40 per share, or 39x forward P/E. Dive into our free research report to see why there are better opportunities than AZTA.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.